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Abstract
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MicroRNA (miRNA) expression varies in association with different tissue types and in diseases.
Having been found in body fluids including blood and cerebrospinal fluid (CSF), miRNAs
constitute potential biomarkers. CSF miRNAs have been proposed as biomarkers for
neurodegenerative diseases; however, there is a lack of consensus about the best candidate miRNA
biomarkers and there has been variability in results from different research centers, perhaps due to
technical factors. Here, we sought to optimize technical parameters for CSF miRNA studies. We
examined different RNA isolation methods and performed miRNA expression profiling with
TaqMan® miRNA Arrays. More specifically, we developed a customized CSF-miRNA lowdensity array (TLDA) panel that contains 47 targets: miRNAs shown previously to be relevant to
neurodegenerative disease, miRNAs that are abundant in CSF, data normalizers, and controls for
potential blood and tissue contamination. The advantages of using this CSF-miRNA TLDA panel
include specificity, sensitivity, fast processing and data analysis, and cost effectiveness. We
optimized technical parameters for this assay. Further, the TLDA panel can be tailored to other
specific purposes. We tested whether the profile of miRNAs in the CSF resembled miRNAs
isolated from brain tissue (hippocampus or cerebellum), blood, or the choroid plexus. We found
that the CSF miRNA expression profile most closely resembles that of choroid plexus tissue,
underscoring the potential importance of choroid plexus-derived signaling through CSF miRNAs.
In summary, the TLDA miRNA array panel will enable evaluation and discovery of CSF miRNA
biomarkers and can potentially be utilized in clinical diagnosis and disease stage monitoring.

Wang-Xia Wang, wwangc@email.uky.edu. Peter T. Nelson, pnels2@email.uky.edu.
Electronic supplementary material The online version of this article (doi:10.1007/s12035-016-0316-2) contains supplementary
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MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression
posttranscriptionally. MiRNAs have been implicated in neurodegenerative diseases, such as
Alzheimer’s disease (AD) [1–4]. MiRNAs are expressed in virtually all known mammalian
cells and can be found in body fluids including serum, cerebrospinal fluid (CSF), saliva,
urine, and breast milk [5], providing a potential opportunity to monitor disease presence and
severity. Studies have shown that miRNAs in serum and plasma are stable at room
temperature for several days and even resistant to RNase treatment [6]. Furthermore, they
are also easier to detect and quantify compared to many protein biomarkers [7]. Thus,
biofluid miRNAs are good candidates for biomarkers.
Despite extensive studies, no miRNA has been firmly established as a clinically relevant
biomarker. Challenges include the complexity of the pathophysiological conditions (various
stages of disease and comorbid pathologies) and also probably heterogeneous human cohorts
[8, 9]. This is particularly true for neurodegenerative diseases. Furthermore, preanalytical
and analytical factors such as sampling methods, specimen storage, RNA isolation and
detection platform, and data normalization all contribute to the mixed outcomes of the
analysis [10–12].
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CSF provides a special context for biomarkers. Already used as an AD biomarker detecting
Aβ, tau, and other analytes, CSF can be obtained via routine lumbar puncture. This clear
proteinaceous fluid is normally in direct contact with the brain after being produced in the
choroid plexus, which exchanges chemicals, proteins, electrolytes, and other molecules with
the blood stream. Thus, it is a critical context for searching biomarkers in association with
CNS diseases.
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Prior studies have analyzed CSF miRNA expression in association with CNS diseases (see
for example [13–19]). These studies employed various isolation and detection methods,
mostly array and deep sequencing-based profiling. Prior studies generated valuable
information in searching for reliable biomarkers. However, contradictory results were also
reported possibly because of biological complexity and the various study designs and
methodological factors. Furthermore, array- and sequencing-based analysis generally have
poorer sensitivity and higher variability for low-quantity RNA inputs, which are typical in
clinic-derived CSF samples.
Here, we describe a custom-made miRNA RT-qPCR panel that can overcome some of the
aforementioned shortcomings in CSF miRNA analysis. The goal was to produce a relatively
economic platform that includes miRNAs known to be present in CSF and include those
miRNAs that previously were implicated as possible biomarkers. We also used this panel to
test whether the miRNA profile of CSF more closely resembles RNA isolated from blood,
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the choroid plexus, or brain tissues derived from the University of Kentucky AD Center
(UK-ADC) biobank.

Materials and Methods
Human Cerebrospinal Fluid, Brain Tissues, and Blood Samples
Human CSF and tissues used in this work were obtained from the UK-ADC biobank and
analyzed in compliance with University of Kentucky Institutional Review board protocol.
Clinical lumbar puncture-derived CSF, blood samples, and snap-frozen brain tissues from
individuals obtained at autopsy, as described previously [20, 21], were coded anonymously.
RNA Isolation from Brain Tissues and Blood

Author Manuscript

Total RNA was extracted from human tissues and blood samples using TRIzol LS reagent
(Thermo Fisher Scientific) following the modified procedure described previously [3, 22,
23]. The RNA concentrations and purity were determined using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Thermo Fisher Scientific).
Testing CSF RNA Isolation Methods
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For the study of RNA isolation technical parameters, ten lumbar puncture-harvested CSF
samples were mixed and spun at 3000 × g for 5 min. Aliquots of 200 μl supernatant from the
mixed sample were used for each RNA isolation procedure. Four replicates were evaluated
for each method. Total RNA was extracted and compared using commercially available kits:
MagMAX™ mirVana™ Total RNA Isolation Kit (Thermo Fisher Scientific), miRCURY™
RNA Isolation Kit–Biofluids (Exiqon), miRNeasy Serum/Plasma Kit (QIAGEN),
NucleoSpin miRNA Plasma (MACHEREYNAGEL), PureLink™ RNA Mini Kit (Thermo
Fisher Scientific), and TRIzol LS reagent (Thermo Fisher Scientific). RNA isolations were
carried out following manufacturers’ instructions except for TRIzol LS reagent which was
done exactly as described previously [3, 22, 23]. RNA isolation experiments were performed
with or without nucleic acid carriers, glycogen, and bacteriophage MS2 RNA (both from
Roche). RNA was eluted or dissolved with 30 μl of nuclease-free water containing RNAsin
(0.5 U/μl, Promega). After a preliminary comparison by single-tube TaqMan® miRNA
assays (data not shown), three kits including miRCURY™ RNA Isolation Kit–Biofluids,
miRNeasy Serum/Plasma Kit, and TRIzol LS reagent were selected for further assessments
by miR-15/107 TaqMan® Low-Density Array (TLDA) analysis [24].
CSF miRNA Profiling Using TaqMan® Array Human MicroRNA A+B Cards Set v3.0
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Clinical CSF samples were collected as described above from additional four controls and
four AD patients and the RNA subjected to TaqMan® Array analysis using Human
MicroRNA A+B Cards Set v3.0 (Life Technologies). CSF RNA was isolated using Exiqon’s
miRCURY™ RNA Isolation Kit (Biofluids) following manufacturer’s protocol. Briefly, 200
μl of CSF was transferred to a fresh tube after centrifuge at 3000 g for 5 min; 60 μl of Lysis
Solution BF was added to the supernatant following a 5-s vortex. After a 3-min incubation, 1
μg of bacteriophage MS2 RNA (carrier, Roche) and 3.5 μl of Cel-miR-39-3p (spike-in RNA,
QIAGEN) at 1.6 × 108 copies/μl was added to the mixture. Protein Precipitation Solution BF
(20 μl) was added, vortex, incubated for 1 min, and centrifuged. The clear supernatant was
Mol Neurobiol. Author manuscript; available in PMC 2018 December 01.
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transferred to a fresh collection tube with addition of 270 μl isopropanol and mixed. Column
binding, washing, and drying were conducted as instructed by the protocol, and RNA was
eluted with 30 μl of nuclease-free water containing 0.5 U/μl RNAsin (Promega). Next, equal
volume of total CSF RNA (3 μl) was reverse transcribed using the TaqMan® MicroRNA
Reverse Transcription Kit (Life Technologies) with Megaplex™ Primer Pools, Human Pool
A and B, respectively (Life Technologies). The resulting complementary DNA (cDNA) was
preamplified using corresponding Human Pool A or B Megaplex™ PreAmp Primers (Life
Technologies) before running the qPCR Array. qPCR was carried out on the ViiA™ 7 RealTime PCR System and quantitative PCR cycle (Cq) was determined using ViiA 7 RUO
software (Life Technologies) with automatic baseline and a fixed threshold set at 0.15.
TaqMan® Low-Density Array (TLDA) Analysis
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Two separate sets of custom-developed TLDA cards were used in the study: miR-15/107
TLDA cards and CSF-miRNA TLDA cards. MiR-15/107 TLDA cards have been described
in detail previously [24]. The CSF-miRNA TLDA card incorporated a combination of
miRNAs related to CSF and neurodegenerative diseases and the miRNA selection was
discussed in “Results.” Standard manufacturer’s protocol was followed for all TLDA cards.
Briefly, 3 μl of CSF RNA or tissue RNA (at 10 ng/μl) was reverse transcribed using
TaqMan® MicroRNA Reverse Transcription Kit (Life Technologies) with pooled specific
RT primers for each panel. An aliquot of RT product was then preamplified using TaqMan®
PreAmp Master Mix (Life Technologies) with pooled preamplification primers (Life
Technologies). RT products with or without preamplification were served as templates.
Premixed template and TaqMan® Universal PCR Master Mix (No AmpErase UNG, Life
Technologies) were transferred to each port of TLDA cards and loaded to each well by
spinning the cards in a centrifuge according to the manufacturer’s instructions. qPCR was
performed using ViiA™ 7 Real-Time PCR System (Life Technologies).
TaqMan® Single-Tube RT-qPCR for Individual miRNAs
Individual miRNA and spike-in Cel-miR-39 were subjected to single-tube TaqMan® RTqPCR assay (LifeTechnologies) according to the manufacturer’s instructions. Equal volume
of CSF RNA (3 μl) for reverse transcription and qPCR was performed in triplicate.
Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE)
was followed throughout all the RT-qPCR procedure [25].
Data and Statistical Analysis

Author Manuscript

Raw PCR Cq values from custom or inventory array cards were first determined using ViiA
7 RUO software (Life Technologies) with automatic baseline and threshold set at 0.15. Data
that failed QC, including those such as bad passive reference signal and failed in exponential
algorithm and thresholding algorithm (amplification too early or too late, low amplification
or no amplification), were treated as undetectable in the analysis. Outliers such as a data
point that is much higher or much lower in Cq among replicates in the data set was also
examined manually, and an amplification curve that was abnormal (i.e., flat curve which
resulted in low Cq) was also treated as undetectable. DataAssist® software (Life
Technologies) was employed to further analyze miRNA array data. A Cq value equal to or
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greater than 32 was considered as undetectable. The global mean normalization method [26]
was selected and a Cq cutoff was set at 35 for inventory and miR-15/107 custom TLDA
cards and 32 for CSF-miRNA TLDA cards (e.g., a Cq value equal to or more than 32 was
considered as undetectable in custom CSF-miRNA TDLA arrays). Correlation coefficient
(R2) of the datasets from customized CSF panel and inventory array cards was obtained
using linear regression function.
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Welch’s two-sample t test was used to evaluate the difference of the mean and total qPCR
array Cq data between the control and AD groups. To determine the differential expression
pattern between CSF and tissues, array data were evaluated using an unpaired Student’s t
test. Hierarchical clustering based on the similarity of miRNA expression patterns was
calculated using Pearson’s distance-Average Linkage. Benjamini–Hochberg tests were used
to control false discovery rate (FDR). p value that is less than 0.05 was considered as
statistically significant.
Correlation coefficient (R2) of miRNA expression pattern between CSF and each individual
tissue group was obtained using linear regression function, and evaluation of correlations
between CSF and various nonindependent tissues was done using confidence intervals
according to the method described by Zou [27].

Results
Empirical Evaluation of CSF RNA Isolation Methods

Author Manuscript

Isolating quality RNA is a critical first step in studying CSF miRNA. The three most
effective kits in our hands were as follows: Exiqon’s miRCURY™ RNA Isolation Kit–
Biofluids; QIAGEN’s miRNeasy Serum/Plasma Kit; and Thermo Fisher Scientific’s
TRIzol® LS Reagent. Because the content of RNA is generally very low in clinical CSF
samples, NanoDrop or other methods of concentration measurements were not sensitive
enough for assessing the quantity and quality of CSF RNA. Instead, we used customized
miR-15/107 TaqMan® Low-Density Array (TLDA, format 24; Life Technologies) [24] to
assess the quantity and quality of CSF RNA isolations. Figure 1 illustrates the procedure
used in evaluating CSF RNA isolation. RNA quantity and quality were defined by the
following standards: (1) low quantification cycle (Cq); (2) high ΔCq above the background;
(3) low technical variability (standard deviation) among replicates.
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Nucleic acid carriers are additives that enhance the yield of RNA isolation, which is
particularly helpful in biological samples with low-concentration RNAs. We evaluated two
different carriers, glycogen and bacteriophage MS2 RNA. Both MS2 RNA and glycogen
carriers enhanced the RNA yield (Suppl. Table 1), with MS2 RNA carrier slightly increasing
technical background levels (Table 1). Next, we tested the consistency of each RNA
isolation method. Four technical replicate isolations were carried out and TLDA array
qPCRs were performed. All three tested methods gave high consistency and there was no
statistically significant difference among the isolation methods tested although some trends
were noted (Fig. 2a, Table 2). TRIzol isolation seemed to perform better as judged by the
trends for lower background (high Cq in background), higher ΔCq above background, and
better consistency among replicate isolations (smaller STDEV). When comparing qPCR Cq
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from different isolation methods, they generally agreed with each other, but were far from
perfect (Fig. 2b). From our data, it is clearly important to use one selected method
consistently throughout a group of samples. On the other hand, when validating the results,
it may be necessary to use a different approach, to avoid the inherent bias or false positives/
negatives generated from the same isolation and detection systems.
In summary, the different methods appear to each have separate strengths and weaknesses
(Table 3). Overall, TRIzol LS provided slightly more consistent results but it involves a
phenol/chloroform step and is technically challenging to obtain a “clean” prep with that
method. By contrast, miRCURY stands out for its easy and fast isolation procedure, good
quality/quantity RNA, and a lack of organic solvent step in the process. We selected the
miRCURY method with MS2 RNA carrier for further studies.

Author Manuscript

Preamplification Increases the Sensitivity and Uniformity of CSF miRNA Detection
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We employed TaqMan® miRNA single-tube assays and TLDA panel to assess CSF
miRNAs. Mindful of the challenge of combining both high technical sensitivity and low
sample-to-sample variability, TaqMan® assays were tested with or without preamplification.
Preamplification is an intermediate step after reverse transcription and before qPCR in
which cDNA can be enriched over several orders of magnitude, theoretically without
disturbing the relative expression of the different miRNAs (Suppl. Fig. 1 and [28]). For
detecting minute quantities of miRNA, preamplification greatly enhances the detection
power of qPCR and data uniformity [28]. As showed in Fig. 3, Cq of most miRNAs in the
miR-15/107 TLDA panel fell to the background levels without preamplification. In contrast,
preamplification improved detection sensitivity by several Cq values. Thus, for most of the
miRNA species, preamplification is a necessary step when assessing CSF RNA using RTqPCR.
CSF miRNA Exploratory Profiling Using TaqMan® Array Human MicroRNA A+B Cards Set
v3.0

Author Manuscript

In order to better control technical variables and to assess the repertoire of miRNAs
detectable with TaqMan® RT-qPCR assays in CSF, we ran a set of discovery (exploratory)
profiling arrays using clinical CSF samples from four controls and four AD patients. Total
RNA was extracted from CSF using Exiqon’s miRCURY™ RNA Isolation Kit (Biofluids).
MS2 RNA was used as additive and C. elegans Cel-miR-39 was spiked in to monitor the
isolation efficiency. TaqMan® RT-qPCR of Cel-miR-39 using the same volume (3 μl) of
isolated RNAs gave similar Cq values across eight isolates with a standard deviation of 0.2
(Suppl. Table 2), indicating a consistent RNA isolation of all CSF samples. This was also
evident by NanoDrop estimation of RNA concentrations.
In the TaqMan® RT-qPCR miRNA results, a miRNA with Cq equal to or more than 35 was
considered as undetectable. A miRNA was determined to be detectable in CSF if it was
present in more than three arrays (out of eight). Using this cutoff, 130 and 63 miRNAs were
detected in Card A and Card B, respectively. There was a small but statistically significant
difference in median Cq of miRNA expression between the control and AD groups (Fig. 4).
Total miRNA content (represented by total Cq values) was also less abundant in AD group
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(higher Cq value). However, most individual miRNAs were not expressed differently
between the samples (using the criterion of fold change ≥ 2, p ≤ 0.05), with the important
caveat of the small sample size (Suppl. Excel file 1).
Most abundant miRNAs in CSF were identified by ranking average Cq values of all samples.
The most abundant miRNAs (Table 4) included miR-204, miR-1274B, miR-16, miR-146a,
miR-150, miR-223, miR-17, and miR-21 as described previously [13, 19]. The complete list
of all detectable miRNAs can be found in supplemental Excel file 2.
The exploratory profiling also enabled us to select potential CSF-specific “housekeeping”
miRNAs for data normalization. Table 5 shows miRNAs displaying relatively constant levels
across both the control and AD groups and within the group as judged by their smaller
standard deviations.
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A CSF-miRNA Panel to Study miRNAs in the Context of Alzheimer’s Disease
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We chose customized TaqMan® miRNA RT-qPCR low-density array format 48 (Life
Technologies) as the platform for studying CSF miRNAs relevant to AD. This PCR-based
expression platform can simultaneously analyze eight samples and accommodate a total of
47 miRNAs plus one mandatory control (U6) per sample. The following criteria were used
to select miRNAs for the panel (Table 6): (1) miRNA is detectable in CSF based on our
profiling and existing literature; (2) miRNA was previously associated with AD (in tissue or
CSF or both) or other neurodegenerative pathology; (3) miRNA is predicted to target genes
critical to AD pathways (e.g., MAPTau, BACE1); (4) miRNA belongs to miR-15/107 or
miR-29 family which are hypothesized to be perturbed and/or involved in neurodegenerative
diseases; (5) miRNA is particularly brain-enriched; (6) miRNA is a potential normalizer
(CSF housekeeping miRNAs); (7) “contamination” controls; and (8) ubiquitously expressed
RNA species. MiRNAs that meet at least one of the above criteria were selected for the
panel. These miRNAs plus U6 were custom-made into a low-density array card, and primers
for RT and preamplification were prepared by Life Technologies® company.
Performance of CSF-miRNA Panel
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To test the performance of the CSF-miRNA panel, the eight CSF samples that were used for
profiling previously (four ADs, four controls) were tested using the novel platform. The
CSF-miRNA panel TLDA analysis generated comparable Cq values as that of the inventory
TaqMan® array cards. The panel seemed to be more sensitive as the overall average Cq was
2.4 lower than that of the inventory cards (Suppl. Table 3). There was a generally good
correlation of miRNAs detected by both methods as indicated by Pearson correlation
coefficient R squared (R2) (Fig. 5, Suppl. Table 3). However, several miRNAs showed a
discrepancy which could be a result of a difference in primer pool size. Furthermore, primer
interaction was observed with the custom-made CSF-miRNA panels (data not shown).
Detection of Tissue miRNAs Using CSF-miRNA Panel
RNA samples derived from the human hippocampus (two cases), cerebellum (two cases),
and choroid plexus (four cases) and snap-frozen at autopsy and clinical blood drawn in a
clinic and then frozen (two cases) were subjected to CSF-miRNA panel TLDA analysis.
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Although total RNA is much more abundant in tissue compared with that in CSF and it does
not require preamplification to obtain a good readout data from these tissue samples, the RTqPCR analyses followed the same procedure as that for CSF including the preamplification
step to maintain the technical consistency. Most miRNAs in the CSF-miRNA panels were
detected in brain tissues and blood samples. As expected, brain-specific or enriched
miRNAs in the CSF panel, such as miR-124a, miR-9, and miR-125a, were not detected or
with very low levels in the blood samples (Suppl. file 3). Several miRNAs displayed similar
expression patterns in CSF and the choroid plexus (Suppl. file 3). For example, miR-1298
was detected in CSF and the choroid plexus, but not detected in the blood and cerebellum
and was very low in the hippocampus; miR-34b and miR-34c also had higher expression
levels in CSF and the choroid plexus than those in other tested tissues. Neuronal enriched
miR-124a has a very low level in both CSF and the choroid plexus, as well as in the blood
samples as expected. Several inflammatory/immunity-related miRNAs, such as miR-21,
miR-223, miR-150, miR-155, miR-146a, miR-142-5p, and miR-142-3p, were all detected in
tested brain tissues, but had relatively high levels in CSF and the choroid plexus. In addition,
miR-204 and miR-1274B seemed to have higher levels in all brain tissues including CSF.
Hierarchical clustering (Pearson’s distance-Average Linkage) demonstrated that among the
tested tissues, CSF miRNAs are clustered closely to the choroid plexus (Fig. 6) indicating a
strong relationship to the organ that generates CSF. Correlation coefficient (R2) of miRNA
expression pattern between CSF and various tissues (Fig. 7) also indicated a close
correlation (R2 = 0.4567) between CSF and choroid plexus miRNA expression. A
comparison of all the correlations between CSF and tissues showed that the correlation
between miRNAs profiled in CSF and the choroid plexus were statistically significant (p =
0.019) [27]. The close correlation of CSF miRNA profile with the choroid plexus miRNA
profile was further confirmed in a separate experiment which was carried out retrospectively
after the initial evaluations. Using different CSF and tissue samples (Suppl. Fig. 3, Suppl.
file 4), it was demonstrated that the CSF miRNA profile had a much stronger correlation
coefficient with that of the choroid plexus (R2 = 0.5694) than with that of the cerebellum (R2
= 0.1583). The difference between these two correlations was statistically significant (p =
0.0005) [27].

Discussion
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Our study introduces a novel miRNA expression profiling platform designed for relatively
efficient use in the context of CSF miRNA profiling. We recommend a technical pipeline
that includes preanalytical parameters, normalization, and expression profile optimization.
The TLDA returns results that are particularly tailored for the study of CSF miRNAs. We
found for the first time that CSF miRNA profile is relatively closely correlated with the
profile of miRNAs in the choroid plexus, in comparison to the samples of the hippocampus
or cerebellum or blood that we evaluated. Since the TLDA is sensitive and characterized by
relatively low technical variability and queries miRNAs that previously were shown to be
relevant to neurodegenerative diseases, it could provide a robust platform for CSF analyses
in conditions such as AD.
There are potential limitations to the present study. We underscore that there is no perfect
miRNA profiling technique—because of the low levels of RNA in the CSF, there is a
Mol Neurobiol. Author manuscript; available in PMC 2018 December 01.
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necessary tradeoff of sensitivity and technical variability. We previously have reported some
of the technical differences that can be seen when data from different profiling platforms are
compared [22, 29, 30]. Further, the use of TLDA cards lacks the ability of some other
methods (such as RNA-Seq) to detect novel miRNAs, being limited to the 47 miRNAs on
the array card. Yet the panel can be refined to include other newly discovered miRNA
biomarkers when necessary. Finally, there are imperfections in the RNA amplification
especially when the primers were multiplexed. For all the limitations of any given method,
we note that there now have been a number of prior studies of CSF miRNAs and other
biofluid miRNA detection methods were reported previously [13–19], providing incentive
for the field to achieve a standardized approach.
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Among the available miRNA profiling platforms, RT-qPCR is relatively sensitive and
economically viable. This method is particularly useful when the RNA input is limited, such
as in the case of CSF RNA. There are two distinct miRNA RT-qPCR platforms currently
widely used in the field. TaqMan® miRNA RT-qPCR assay (Life Technologies) employs a
sequence-specific stem-loop RT primer to generate miRNA cDNA template followed by
qPCR using sequence-specific primers and probes for quantification. Another type of
platform uses a universal tailing and reverse transcription reaction followed by qPCR with
sequence-specific PCR primers. The first method proves to be more specific while the latter
is more sensitive, but less specific [31]. We chose TaqMan® miRNA RT-qPCR assay (Life
Technologies) as our detection platform for its high specificity. Here, we reported results
using TaqMan® Array Human MicroRNA A and B cards to profile eight clinical (four
controls and four ADs) CSF miRNAs.
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Our qPCR array profiling detected 193 miRNAs, ~25% of miRNA species spotted on A and
B cards (which tested a total 766 miRNAs). This is fewer than the detectable miRNAs
obtained by Denk and the colleagues who profiled CSF miRNA using similar TaqMan® RTqPCR-based OpenArray platform [19] which can profile more miRNAs at once (1178
miRNAs of OpenArray vs 766 of miRNA array Card A and B combined). However, most of
the detectable miRNA in our profiling were also detected in OpenArray platform. The main
purpose of this profiling was to provide necessary information with regard to detectability,
abundance, and potential normalizers for the design of an optimized CSF-miRNA panel.
Among the detectable miRNAs, several miRNAs, such as miR-1274B, miR-30b, and
miR-30c, showed little variation from case to case and were each relatively abundant in CSF
(Cq less than 30). These miRNAs were identified as potential normalizers in the panel.
Notably, miR-1274B was also suggested as a potential normalizer by Denk et al. [19].
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We conclude that TLDA-based PCR assays provide a relatively robust and sensitive platform
for CSF miRNA analyses. Most prior studies have focused on “endpoints” rather than
optimizing technical parameters. Here, we evaluated separate RNA isolation techniques and
RNA carriers. The TLDA panel we propose incorporates the miRNAs highlighted as
potentially important by prior studies and provides a context for further study. This
constitutes a relatively high throughput assay that enables potential study design with greater
numbers of clinical controls—including cognitively intact individuals with and without
pathologic changes, as well as dementia controls with a variety of different conditions
reflecting the common brain diseases of aging. Finally, we found it interesting that the
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miRNA profile of CSF more closely resembled (among the samples tested) those of the
choroid plexus than those of either brain tissues or blood. MiRNAs are very powerful and
promiscuous agents that regulate global gene expression. Our findings raise the provocative
hypothesis that the choroid plexus can influence CNS cells via secretion of miRNAs into the
CSF, a mechanism that could contribute to both healthy and diseased states in the brain.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.

Workflow for testing CSF RNA isolation methods
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Fig. 2.

Author Manuscript

Consistency of CSF RNA isolation methods. Four replicate isolations were carried out using
the same CSF sample for each isolation method. The isolated CSF RNAs were tested using
the miR-15/107 TLDA analysis. Cq data of each array were plotted against each other, and
the coefficient of correlation (R2) of the two data sets calculated. A representative plot from
each method was shown. RNA isolations within each method (a) were highly consistent,
with slightly higher variance between the different isolation methods (b) with variance being
greater at low-quantity (high-Cq) miRNAs
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Preamplification increases the detection sensitivity MiR-15/107 TLDA analysis of cDNA
template generated from the same RT product with or without preamplification are shown.
The Cq of most miRNAs from the templates without preamplification (red dots and line) in
miR-15/107 TDLA cards fell to the background (gray dots and line) level (Cq = 35); in
contrast, preamplification array (brown dots and line) improved detection by several Cq
values
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Fig. 4.
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CSF miRNA profiling using TaqMan® Array Human MicroRNA A+B Cards (Set v3.0).
Eight clinical lumbar puncture-harvested CSF (four ADs and four controls) were subject to
miRNA TaqMan® Array. Overall expression level of miRNAs was slightly lower in AD
patients (the higher the Cq the lower the expression level)
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Fig. 5.

Detection of miRNA using CSF-miRNA panel is comparable with inventory TaqMan®
Array Cards. The same eight clinical lumbar puncture-harvested CSF RNAs were analyzed
using inventory array cards and customized CSF-miRNA TLDA panel. Cq data of the same
miRNAs (a, b) and same cases (c, d) generated by CSF-miRNA panel were generally well
correlated with that of inventory array cards
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Hierarchical clustering of miRNA expression in CSF, blood, and tissue RNA was analyzed
using CSF-miRNA TLDA. Cq values of each array were normalized by global mean
method. Hierarchical clustering of expression patterns was determined by Pearson’s
distance-average linkage. The heatmap indicated that miRNA patterns of CSF were
relatively similar to that of the choroid plexus, the organ that generates CSF. CSF, blood,
hippocampus, and cerebellum samples are marked in the same colors
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Fig. 7.

Correlation of miRNAs detected in CSF and tissues using CSF-miRNA panel CSF and
tissue RNAs was analyzed using CSF-miRNA TLDA. Average Cq values of each sample
group were plotted against each other, and the coefficient correlation (R2) of two data sets
were obtained by linear regression
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Comparison of CSF RNA isolated by various methods on miR-15/107 TLDA cards (n = 4)
Isolation
method

Carrier

Carrier only w/
PreAmp

CSF RNA w/o
PreAmp

CSF RNA w/
PreAmp

ΔCq above
background

miRNeasy

MS2

32.77

32.93

25.34

−7.44

miRCURY

MS2

32.95

33.25

26.12

−6.82

TRIzol LS

MS2

33.14

N.D.

25.89

−7.25

Glycogen

33.93

N.D.

26.77

−7.16
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Consistency of RNA isolation by each method (n = 4)
Average Cq

STDEV

STDEV range

miRNeasy

25.66

0.65

0.21–1.94

miRCURY

26.08

0.77

0.14–3.04

TRIzol LS

27.09

0.48

0.16–2.31
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Isolation method comparison
Isolation method

RNA

Easiness

Organic solvent

Time

miRCURY

Good

+++

No

Fast

miRNeasy

Good

++

Yes

Fair

Trizol LS

Good

−

Yes

Lengthy

Author Manuscript
Author Manuscript
Author Manuscript
Mol Neurobiol. Author manuscript; available in PMC 2018 December 01.

Wang et al.

Page 23

Table 4

Author Manuscript

Top 50 most abundant miRNAs in CSF identified by TaqMan® miRNA RT-qPCR arrays

Author Manuscript
Author Manuscript

Rank

miRNA

Cq

Rank

miRNA

Cq

1

hsa-miR-204

24.4

26

hsa-let-7b

29.3

2

hsa-miR-1274B

25.3

27

hsa-miR-92a

29.4

3

hsa-miR-17

26.6

28

hsa-miR-20a

29.5

4

hsa-miR-106a

26.8

29

hsa-miR-211

29.5

5

hsa-miR-19b

27.0

30

hsa-miR-425-5p

29.6

6

hsa-miR-223

27.1

31

hsa-miR-99a

29.6

7

hsa-miR-1298

27.3

32

hsa-miR-30b

29.6

8

hsa-miR-720

27.5

33

hsa-miR-484

29.7

9

hsa-miR-21

27.6

34

hsa-miR-571

29.7

10

hsa-miR-661

27.8

35

hsa-miR-29a

29.8

11

hsa-miR-146a

28.1

36

hsa-miR-100

29.9

12

hsa-miR-150

28.2

37

hsa-miR-346

29.9

13

hsa-miR-30a-5p

28.5

38

hsa-miR-1274A

29.9

14

hsa-miR-9#

28.5

39

hsa-miR-338-5P

30.0

15

hsa-miR-24

28.6

40

hsa-miR-638

30.1

16

hsa-miR-320

28.6

41

hsa-miR-574-3p

30.1

17

hsa-miR-34b

28.7

42

hsa-miR-125b

30.2

18

hsa-miR-30c

28.8

43

hsa-miR-485-3p

30.2

19

hsa-miR-16

28.8

44

hsa-miR-146b

30.3

20

hsa-miR-1825

28.9

45

hsa-miR-26a

30.3

21

hsa-miR-487a

29.1

46

hsa-miR-885-5p

30.3

22

hsa-miR-222

29.1

47

hsa-miR-143

30.4

23

hsa-miR-342-3p

29.1

48

hsa-miR-34a

30.4

24

hsa-miR-30a-3p

29.2

49

hsa-miR-1275

30.5

25

hsa-miR-648

29.3

50

hsa-miR-145

30.5
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Top 10 most stable miRNAs in CSF
miRNA

Rank

Cq-AD

STDEV-AD

Cq-ctrl

STDEV-ctrl

Cq-all

STDEV-all

hsa-miR-152

88

32.0

0.14

32.0

0.19

32.0

0.16

hsa-miR-618

89

32.0

0.38

32.0

0.06

32.0

0.26

hsa-miR-30c

18

28.6

0.07

29.0

0.22

28.8

0.27

hsa-miR-9#

14

28.6

0.31

28.4

0.26

28.5

0.28

hsa-miR-208

193

34.8

0.50

34.9

0.15

34.8

0.35

hsa-miR-1274B

2

25.3

0.20

25.4

0.50

25.3

0.35

hsa-miR-30a-5p

13

28.6

0.41

28.4

0.38

28.5

0.38

hsa-miR-204

1

24.2

0.17

24.7

0.39

24.4

0.39

hsa-miR-30b

32

29.5

0.42

29.7

0.39

29.6

0.40

hsa-miR-338-5P

39

29.9

0.37

30.1

0.48

30.0

0.42
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Specific CSF miRNA panel for studying neurodegenerative diseases

Author Manuscript
Author Manuscript
Author Manuscript

Assay ID

miRNA

Selection criteria

Note

000377

hsa-let-7a

1, 8

ND in our array

002619

hsa-let-7b

1, 8

000379

hsa-let-7c

1, 8

000382

hsa-let-7f

1, 2, 8

000439

hsa-miR-103

1, 2, 3, 4

002169

hsa-miR-106a

1, 2, 3, 4

000443

hsa-miR-107

1, 2, 3

000449

hsa-miR-125b

1, 2, 5

002884

hsa-miR-1274B

1, 6

002861

hsa-miR-1298

1, 2

000457

hsa-miR-132

1, 2, 3

000464

hsa-miR-142-3p

1, 2

002248

hsa-miR-142-5p

1

000468

hsa-miR-146a

1, 2

001097

hsa-miR-146b

1, 2

000473

hsa-miR-150

1

002623

hsa-miR-155

1, 2

000389

hsa-miR-15a

1, 2, 3, 4

000390

hsa-miR-15b

1, 2, 3, 4

000391

hsa-miR-16

1, 2, 3, 4

002308

hsa-miR-17

1, 3

000480

hsa-miR-181a

1, 2

ND in our array

000482

hsa-miR-181c

1, 2

ND in our array

000494

hsa-miR-195

1, 2, 3, 4

000396

hsa-miR-19b

1, 2, 3

000508

hsa-miR-204

1, 3, 6

000580

hsa-miR-20a

1, 3

000397

hsa-miR-21

1, 2, 7

002295

hsa-miR-223

1, 2, 7

000402

hsa-miR-24

1, 7

000408

hsa-miR-27a

1, 2

002112

hsa-miR-29a

1, 2, 4

000413

hsa-miR-29b

1, 2, 4

000587

hsa-miR-29c

1, 2, 4

000416

hsa-miR-30a-3p

1, 2, 6

000417

hsa-miR-30a-5p

1, 2

000602

hsa-miR-30b

1, 2, 6

000419

hsa-miR-30c

1, 2, 6

000420

hsa-miR-30d

1, 2

ND in our array

ND in our array

ND in our array

ND in our array
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Assay ID

miRNA

Selection criteria

Note

000422

hsa-miR-30e-3p

1

000426

hsa-miR-34a

1, 2

002102

hsa-miR-34b

1, 2

000428

hsa-miR-34c

1, 2

001043

hsa-miR-497

1, 2, 3, 4

000583

hsa-miR-9

1, 2, 5

ND in our array

001182

mmu-miR-124a

1, 2, 5

ND in our array

001141

mmu-miR-451

1, 2

1 miRNA is detectable in CSF based on our profiling and existing literature, 2 miRNAwas previously associated with AD (in tissue or CSF or both)
or other neurodegenerative pathology, 3 miRNA is predicted to target genes critical to AD pathways (e.g., MAPTau, BACE1), 4 miRNA belongs to
miR-15/107 or miR-29 family which are hypothesized to be perturbed and/or involved in neurodegenerative diseases, 5 miRNA is particularly
brain-enriched, 6 miRNA is a potential normalizer (CSF housekeeping miRNAs), 7 contamination controls, 8 ubiquitously expressed RNA species,
ND not detected
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